Table 2. Samples with A20 deletions and/or the absence of A20 by immunohistochemistry.
Sample No. | Diagnosis | A20 deletion | A20 expression | EBER1 (ISH) | LMP-1 | EBNA-2 |
1 | PAL | Homozygous loss | − | + | + | + |
2 | PAL | LOH | − | + | + | + |
3 | PAL | LOH | +/− | + | + | + |
4 | PAL | LOH | +/− | + | + | + |
5 | NKTL | Homozygous loss | u.d. | + | − | − |
6 | NKTL | LOH | u.d. | + | − | − |
7 | NKTL | LOH | +/− | + | − | − |
8 | DLBCL-e | LOH | + | + | + | − |
9 | MTX-LPD | normal | − | + | + | − |
Abbreviations: PAL, pyothorax-associated lymphoma; NKTL, NK/T cell lymphoma, nasal type; DLBCL-e, EBV positive diffuse large B-cell lymphoma of the elderly; MTX-LPD, methotrexate-related lymphoproliferative disorders; LOH, loss of heterozygosity; EBER1, Epstein-Barr virus encoded RNA1; LMP-1, latent membrane protein-1; EBNA-2, EBV nuclear antigen-2; +, positive (50% or more); p+, intermediate expression (less than 50%); −, negative (0%); +/−, equivocal positive; u.d., undetermined.